Compare Flagstar Bank NA (FLG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Mesoblast Limited — how do they compare? Flagstar Bank NA trades at $14.18 (market cap $5.89B), while Mesoblast Limited trades at $16.83 (market cap $2.21B). The key difference: Flagstar Bank NA is far larger — about 2.7× Mesoblast Limited's market cap, and Flagstar Bank NA pays a 0.28% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FLG | MESO | |
|---|---|---|
Market Cap | $5.89B | $2.21B |
Sector | Financials | Technology |
52-Week High | $15.36 | $20.96 |
52-Week Low | $10.72 | $12.88 |
Dividend Yield | 0.28% | — |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.20, up 1.36% today, with a bullish technical signal and analyst consensus price target of $16.85 suggesting 19% upside. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and strategic operational enhancements signal management confidence in long-term value.
The outlook is cautiously optimistic, with profitability improving and valuation attractive at a P/B of 0.77. Risks include earnings volatility, competitive pressures, and economic sensitivity. Institutional sentiment leans bullish, with no sell ratings, though execution on guidance remains key for sustained momentum.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
